New Draft Regulatory Guidance Would Speed Breast Cancer Drug Approval

The Foundation for the National Institutes of Health announced the release of a draft guidance by the Food and Drug Administration on a new breast cancer drug trial design.

Advertisement

The new approach would reduce the time and cost of bringing new treatments to patients.

Click here to read the full story in Becker’s Hospital Review on the FDA.

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.